Skip to main content

/ health information/ Group items tagged NHS-deal-with-Vertex-Pharmaceuticals

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

Vertex Cystic Fibrosis Therapies Face UK Access Hurdle - 0 views

www.pharmacy.biz/...t-new-cystic-fibrosis-patients

NICE-draft-guidance-on-cystic-fibrosis-drugs Vertex-Pharmaceuticals-treatments NICE-assessment-of-cystic-fibrosis-therapies NHS-deal-with-Vertex-Pharmaceuticals

shared by pharmacybiz on 14 Nov 23 - No Cached

pharmacybiz on 14 Nov 23

Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK. A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients. Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older. The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.

<div class="cArrow"> </div><div class="cContentInner">Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK. A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients. Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older. The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.</div>

...

Cancel

1 - 1 of 1

Showing 20▼ items per page

Related searches